Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease
CompanyDeals

Royal Philips and Suzhou Peixin Collaborate on AI-Powered Interventional Therapy Platform for Structural Heart Disease

YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
CompanyDrug

YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study

CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings
CompanyLegal / IP

CARsgen Therapeutics Secures European Patent for GPC3 CAR-T Technology After Successful Opposition Proceedings

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China
Others

Eisai Announces Commercial Release of Urece (Dotinurad) from Suzhou Facility in China

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies
CompanyDrug

InnoCare Pharma Receives FDA Approval for Mesutoclax in Myeloid Malignancies

Pfizer and Astellas' Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
CompanyDrug

Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer

Bayer's Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms
CompanyDrug

Bayer’s Elinzanetant Granted UK Marketing Authorization for Menopause-Related Vasomotor Symptoms

AbbVie Licenses IGI Therapeutics' ISB 2001 for Oncology and Autoimmune Diseases
CompanyDeals

AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases

Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC
CompanyDrug

Jiangsu Jibeier Receives NMPA Approval for Clinical Trials of JJH201601 Liposome in Advanced HNSCC

Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma
CompanyDrug

Fosun Pharmaceutical Launches Phase III Study for Fumaining in Pediatric Low-Grade Glioma

BeOne Medicines' Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma
CompanyDrug

BeOne Medicines’ Tevimbra Approved by European Commission for Nasopharyngeal Carcinoma

Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific
CompanyMedical Device

Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific